Target Name: CD58
NCBI ID: G965
Other Name(s): Surface glycoprotein LFA-3 | LFA3_HUMAN | CD58 molecule, transcript variant 1 | CD58 molecule | Ag3 | ag3 | LFA3 | Lymphocyte function-associated antigen 3 (isoform 1) | CD58 variant 1 | CD58 molecule, transcript variant X1 | Lymphocyte function-associated antigen 3 | surface glycoprotein LFA-3 | CD58 antigen, (lymphocyte function-associated antigen 3) | Lymphocyte function-associated antigen 3 (CD58) (isoform X1) | CD58 variant X1 | LFA-3

CD58: A Surface Glycoprotein LFA-3 as a Potential Drug Target and Biomarker

Introduction

Surface glycoproteins (SGPs) are a family of proteins that play a crucial role in cell-cell and cell-extracellular matrix (ECM) interactions, including cell adhesion, migration, and tissue engineering. Glycoproteins are involved in many essential biological processes, including cell signaling, migration, and inflammation. The LFA-3 (Leucine-rich repeat-containing alpha-3) protein is a type of SGOPROTE (Glycoprotein subfamily 3) that is expressed in various tissues and cell types. In this article, we discuss CD58 (Surface glycoprotein LFA-3), a protein that has been identified as a potential drug target and biomarker.

CD58: Structure and Function

CD58 is a 14-kDa protein that is composed of 155 amino acids. It has a characteristic LFA-3 repeat that is composed of three Leucine-rich repeats followed by an Ala-rich terminal region (Figure 1). The LFA-3 repeat is a common structural feature that is found in many SGOPROTE proteins, including CD58.

CD58 is a cell surface protein that is involved in various cellular processes, including cell adhesion, migration, and signaling. It is expressed in various tissues, including brain, heart, liver, and cancer cells. It has been shown to play a role in several biological processes, including the regulation of cell adhesion, the development of cancer, and the regulation of inflammation.

CD58 has also been shown to be involved in signaling pathways. It has been shown to be involved in the PI3K/Akt signaling pathway, which is a well-known signaling pathway that is involved in various cellular processes, including cell growth, survival, and angiogenesis. Additionally, CD58 has been shown to be involved in the TGF-β signaling pathway, which is involved in cell signaling, including cell adhesion and migration.

CD58 has also been shown to be involved in the regulation of cell death. It has been shown to be involved in the production of reactive oxygen species (ROS), which can cause cell death. Additionally, CD58 has been shown to be involved in the regulation of cell survival by suppressing the production of pro-apoptotic proteins.

CD58 as a Potential Drug Target

CD58 has been shown to be involved in several biological processes that could make it an attractive drug target. For example, CD58 has been shown to be involved in the regulation of cell adhesion, which is a critical process for the development of cancer. Additionally, CD58 has been shown to be involved in the regulation of cell migration, which is a critical process for the development of cancer.

CD58 has also been shown to be involved in the regulation of cell signaling pathways, including the PI3K/Akt and TGF-β signaling pathways. Activating these signaling pathways can lead to the growth and survival of cancer cells. Therefore, inhibiting these signaling pathways may be an effective way to treat cancer.

CD58 has also been shown to be involved in the regulation of cell death. Pro-apoptotic proteins, such as Bax, can cause cell death, but CD58 can inhibit their production. This may provide an additional mechanism of cancer treatment by targeting the regulation of cell death.

CD58 as a Biomarker

CD58 has also been shown to be involved in the regulation of cellular processes that can serve as biomarkers for cancer. For example, CD58 has

Protein Name: CD58 Molecule

Functions: Ligand of the T-lymphocyte CD2 glycoprotein. This interaction is important in mediating thymocyte interactions with thymic epithelial cells, antigen-independent and -dependent interactions of T-lymphocytes with target cells and antigen-presenting cells and the T-lymphocyte rosetting with erythrocytes. In addition, the LFA-3/CD2 interaction may prime response by both the CD2+ and LFA-3+ cells

More Common Targets

CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5